L718q/v mutation in exon 18 of egfr mediates resistance to osimertinib: clinical features and treatment

HIGHLIGHTS

• who: Meihui Li from the Hospital of the University of the Chinese Academy of Sciences (Zhejiang Cancer Hospital), as well as additional patients have published the paper: L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment, in the Journal: (JOURNAL) of December/31,/2021
• future: Due to the limited number of cases considered in this study future studies should explore drugs that more precisely target the L718Q/V mutation of EGFR exon 18.

SUMMARY

Vol.:(0123456789) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.